The Future of Healthcare Consulting: From Advice to Assets

Key Insights

• Firms are shifting from selling people to selling assets. Proprietary data, platforms, joint ventures, and venture investments are where leaders said future value will sit.
• Time and materials is losing its grip. Clients are starting to ask firms to be paid against outcomes, and firms are building partnerships to deliver them.
• AI is already answering part of the brief. The value that survives is proprietary data, scientific conviction, and accountability for results.

---

For most of its history, healthcare consulting has sold one thing: expert time. A client paid for smart people, and the smart people produced answers.

The future of healthcare consulting looks different, and firm leaders are saying so openly.

When Management Consulted asked practice leaders where their firms are headed – in submissions, in conversations, and through independent research for the 2027 Top Healthcare Consulting Firms ranking – the answers kept pointing the same direction. Less billing for hours. More investment in things a firm owns.

The ranking covers the full sector: providers, payers, government health, pharma and biotech, medtech, diagnostics, and digital health. The shift below held across both care delivery and life sciences, though the assets firms are building look different on each side.

Healthcare consulting is becoming a products business. Firms without an asset will be left selling the part of the work AI does cheapest.

The Future of Healthcare Consulting Is Built on Assets, Not Hours

Asked what the market is underestimating, one firm answered with this: consulting is evolving "from selling expertise to delivering reusable capabilities." Clients "increasingly expect advanced tech platforms, proprietary data, embedded analytics and measurable outcomes, not just one-off recommendations." The shift, it concluded, is "from simply having the smartest consultants to most scalable IP."

That shift showed up in what firms said they're building:

• Proprietary data – lab and diagnostic databases, benchmarks, and syndicated market reports clients can't assemble themselves
• Client-ready tools – one leader told a team member not to worry about spending $500 on AI tools, because "you're going to build a tool for a client that is almost, you know, a SaaS"
• Joint ventures – one firm paired its expertise and data with a data software company, and the venture now generates revenue on its own
• Venture investing – one firm invests directly in the sector it advises, "reflecting our conviction"

The pattern held on both sides of the market, but the assets differ. In life sciences, the valuable data sits in trials, diagnostics adoption, and pricing. In care delivery, it sits in cost, workforce, and operational benchmarks drawn from many health systems at once.

Neither exists inside the client, which is exactly why a client will pay for it. A firm's people still win the work. An increasing share of the value comes from what the firm owns.

Watch: 2027 Healthcare Consulting Panel

Time and Materials Is Losing Its Grip

The billing model is moving with the assets.

"We think the days of just relying on time and material – those days have gone," one leader told us. "Consulting firms now need to bring a lot more to the table."

Clients are pushing from their side. One leader described clients telling the firm it could have the assignment, "but you will be valued against the actual outcome." Another firm said it is "increasingly putting our fees at risk through various different commercial models."

Neither pretended it's easy. "We need to take on board a higher risk," one said, calling it challenging and still early stage in healthcare.

When a firm puts fees at risk, it needs confidence it can deliver the result – and that confidence usually comes from an asset, not from a team. It also changes who inside a firm matters most. Under time and materials, the partner who sells the most hours wins. Under outcome pricing, the partner who can predict the result wins, and predicting it takes data from prior engagements.

Outcome pricing and owned assets are the same strategy seen from two sides. A firm can't sell results at scale without something repeatable underneath.

---

---

Healthcare Consulting Industry Trends Are Being Set Outside the Firm

The forces shaping where firms invest mostly come from policy, regulation, and client economics.

Pricing policy is reshaping launches. The administration's push for most-favored-nation drug pricing ties U.S. prices to what drugmakers charge abroad. One firm expects it could "reshape global launch strategies," with some manufacturers delaying or reducing launches outside the U.S.

Value is shifting from instruments to clinical adoption. One firm described the center of gravity in life sciences moving "from scientific push to clinical pull": diagnostics and the data around them, not the instruments, "increasingly decide where value lands." Many tools and diagnostics companies are now cash-flow positive after a post-pandemic collapse, which brings private equity in.

Academic medical centers are building regional networks. On the care delivery side, one firm flagged "the changing role of Academic Medical Centers in building regional networks" as underestimated – work that pulls consultants into acquisitions, integration, and operating model design.

Health data rules are changing the work. In Europe, the European Health Data Space regulation sets new requirements for how health data is shared and reused. Leaders working with health authorities and hospitals called integration "a large discussion" and described data platforms, information security, and AI governance as growing lines of work.

These healthcare consulting trends sit inside larger shifts across the profession, covered in our management consulting industry report. What's distinct in healthcare is how directly each one rewards data and tools a firm owns.

A Client Answered a Third of the Brief Before the Firm Started

Here's the uncomfortable part.

One firm sent a client a $300,000 proposal listing the 30 questions the engagement would answer. The client wrote back with an AI model's answers to the first 10 and asked the firm to focus on the other 20.

The leader who told us the story was clear that it's rare. It had happened once. The broader pattern, in that leader's words, is "increase output, not decrease in the number of people" or in fees. But they also called it "a little scary," and it shows where the line is moving.

Clients can now remove the parts of an engagement AI can answer before the firm sees the scope. Model capability keeps climbing, as Stanford HAI's AI Index documents year after year, so the share of a brief AI can answer will keep growing.

So what survives? Three things came through in what leaders told us.

Proprietary data – information an AI model has never seen because it belongs to the firm. Scientific conviction – one firm promises clients "conviction that generalist firms can't" deliver on whether a technology will work clinically and commercially. Another argued AI handles "the low-hanging fruit" but won't replace people who "understand how and why the science works." Accountability – as a third put it, "the client wants a stamp on the report... You're accountable."

People still matter in that picture. "At the end of the day, it's still a people business," that leader said. Another firm warned the market is "underestimating the people required to make [AI] work." AI can answer the question. It can't sign its name to the answer or make a health system act on it.

The firms most exposed are the ones selling what the client just answered for free.

What This Means for Firm Leaders

Name your asset. If your team walked out tomorrow, what would clients still pay for? If the answer is nothing, that's the investment priority.

Price one engagement on outcomes this year. Start where your track record and data are strongest. Learning to price risk takes practice, and clients are already asking.

Assume the client already asked an AI model. Build proposals around the questions it can't answer: the ones that need your data, your conviction, or your accountability.

Build data advantages inside your segment. Assets are segment-specific. Trial and pricing data don't help a health system, and operational benchmarks don't help a biotech. Pick the side of the care delivery and life sciences divide where you'll own something.

Partner for what you can't build. Joint ventures and expert networks let a firm offer assets it would take years to build alone.

The Bottom Line

Healthcare consulting was built on selling expert time. That model isn't disappearing, but it's no longer where firm leaders see the growth.

The value is moving to things firms own: data, tools, and results they'll put fees behind. AI is speeding that shift by answering the parts of the brief that used to fill the first weeks of an engagement.

The next few years will separate firms that own an asset from firms that rent out people. When Management Consulted opens the next ranking cycle, that's the question we'll be asking every firm.

FAQ: The Future of Healthcare Consulting

What is the future of healthcare consulting?

Firms are moving from selling expert time toward owning assets: proprietary data, client-ready tools, joint ventures, venture investments, and outcome-based fees. People still win the work, but more of the value comes from what the firm owns.

What are the biggest healthcare consulting industry trends for 2027?

Outcome-based pricing, investment in proprietary data and tools, pricing policy reshaping drug launches, clinical adoption driving value in diagnostics, regional network building by academic medical centers, and new health data rules.

How big is the healthcare consulting market?

Published estimates vary widely because definitions vary – some include IT services, some exclude life sciences. Management Consulted doesn't publish a single figure. The clearer signal is demand: most firms we heard from said it exceeds what they can deliver.

How is AI changing healthcare consulting?

AI is taking over research and data work inside engagements, and occasionally answers part of a brief before the firm starts. Value is shifting to proprietary data, scientific conviction, and accountability for outcomes. For the wider picture, see our analysis of whether AI is replacing jobs.

How are healthcare consulting firms changing how they charge?

More engagements tie fees to milestones or outcomes, and some firms earn through joint ventures, tools, and investments rather than hours. Time and materials remains common, but leaders described it as a model on its way out.

Does this shift apply to both care delivery and life sciences?

Yes, but the assets differ. Life sciences firms build around trial, diagnostics, and pricing data. Care delivery firms build around cost, workforce, and operational benchmarks. Management Consulted's ranking covers both markets and maps segment leaders separately.

---

Related reading:

• Every Healthcare Consulting Firm Now Claims the Same Differentiator
• Healthcare Clients Stopped Buying Analysis. They're Buying Time.
• Every Firm Wants the Hybrid Hire. Almost None Are Building One.